Clinical Study

S1905- A Phase II Study Of Akr1c3-Activated Prodrug Obi-3424 (Obi-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-All)

Posted Date: May 7, 2021

  • Investigator: Emily Curran
  • Specialties: Cancer, Leukemia, Oncology
  • Type of Study: Drug

The main purpose of this study is to determine how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). The primary outcome measured in this study is complete remission response rate.


Must Have Diagnosis Of Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia (T-All), Zubrod Performance Status 0-3, Adequate Organ Function Per Protocol, Hiv/Hbv/Hcv Must Have Undetectable Viral Load, No Allogeneic Hematopoietic Transplant Within 90 Days, No Chemotherapy Within 14 Days, No Systemic Fungal, Bacterial, Viral Or Other Infection That Is Not Controlled


Leukemia, T-All

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.